Dante Genome Test
Clinical-grade whole genome sequencing with 200+ physician-ready reports
Service · Cloud SaaSCompany source
Company profile
About Dante Labs
Dante Labs is a clinical genomics company that makes whole genome sequencing accessible to individuals and healthcare providers worldwide. Founded in 2016 and headquartered in New York City, the company has sequenced over 100,000 genomes and delivered more than 1.3 million clinical reports to customers in over 100 countries. Dante Labs sequences the entire genome—not just targeted gene panels—at 30X coverage with 99.98% accuracy in ISO 15189-accredited, CLIA-certified, and CAP-accredited laboratories in Europe and the United States. The company's approach addresses situations where standard genetic testing falls short: hereditary conditions that run in families, unexplained symptoms with no clear diagnosis, treatments that aren't working as expected, and proactive health planning. Each genome test generates over 200 physician-ready clinical reports organized by category, including cardiovascular, hereditary cancer, neurological, rare diseases, metabolic, pharmacogenomics, and autoimmune conditions. Results are classified to ACMG standards—the same framework used by major medical institutions—and are automatically updated as new variant-disease associations are discovered. The company also offers RNA profiling and oncology-specific genomic analysis. Dante Labs' mission is to make comprehensive genomic information clinically actionable, helping patients and physicians make informed decisions together. The company has documented clinical outcomes where its genomic data enabled diagnoses at NHS hospitals and changed treatment plans for conditions including Noonan Syndrome, RUNX1 deficiency, GLUT-1 epilepsy, and chemotherapy selection in breast cancer patients.
Company description Dante Labs official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Dante Labs?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Cardiovascular diseases
- Congenital deafness
- Epilepsy
- GJB2-related hearing loss
- GLUT-1 deficiency
- Hereditary cancer
- Long QT Syndrome
- Metabolic disorders
- Neurological conditions
- Noonan Syndrome
- Rare diseases
- RUNX1 deficiency
Who it serves
- Cancer patients
- Clinical teams
- Individual consumers
- Patients with hereditary risk
- Patients with unexplained symptoms
- Physicians
- Proactive health consumers
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
Markets100+ countries globally · Europe · Middle East · United Kingdom · United States
Company sourceOfficial website
Company milestones
Platform expansion
Over 100,000 genomes sequenced. Documented clinical outcomes with NHS genetics teams. CEO Andrea Riposati presented at Italian Tech Week 2023. Recognition in Financial Times Top 25 European Fastest Growing Companies and Sole 24 Ore Growth Leaders.
Partnerships
Recorded partners
- American Society of Human Genetics
- Gene Journal
- International Society for Cell & Gene Therapy
- Nature Communications (publication partner)
- NHS (documented clinical case acceptance at Queen Elizabeth University Hospital Glasgow)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Genome Manager
Patient portal for accessing and managing genomic reports
Platform · Cloud SaaSCompany source
Oncology
Genomic testing for cancer patients
Service · Cloud SaaSCompany source
RNA Profile
RNA sequencing and analysis service
Service · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
100,000+ genomes sequenced
Total genomes processed globally
1.3M+ clinical reports generated
Total reports delivered to patients
99.98% sequencing accuracy
Across all processed genomes
200+ physician-ready reports per genome
Delivered via Genome Manager platform
30X whole genome coverage
Every base pair read 30 times
Angela (Childhood Epilepsy Case)
Diagnosis of GLUT-1 deficiency causing epilepsy in 4-year-old with uncontrolled seizures
Enabled switch from ineffective anticonvulsant medications to targeted ketogenic diet, described as 'life-changing' by patient's mother
Jennifer (Breast Cancer Case)
Pharmacogenomics analysis prevented serious adverse chemotherapy reaction in breast cancer patient
Pre-existing genome data from 2 years prior identified chemotherapy incompatibility, enabling alternative drug selection before treatment began
Leon (Congenital Deafness Case)
Identification of genetic cause of congenital deafness in 12-month-old infant
GJB2 variant identified, providing confirmed diagnosis and basis for early targeted intervention
Neurological Condition Case
Diagnosis of genetic cause of motor difficulties from infancy after all previous tests failed
Genetic variant identified, giving clinical team confirmed diagnosis to act on
Queen Elizabeth University Hospital Glasgow, NHS
Identification of Noonan Syndrome and RUNX1 deficiency (hereditary leukemia risk) in patient with years of inconclusive investigations
Two distinct genetic conditions identified in single test that had gone undetected through all previous investigations, accepted by NHS genetics team
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Andrea Riposati
Chief Executive Officer & Co-founder
06 · Company updates
Updates from Dante Labs
Recent articles published on Dante Labs's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.